ECI2 (Enoyl-CoA delta-isomerase 2) is a mitochondrial enzyme involved in the isomerization of enoyl-CoA intermediates during lipid metabolism. The FITC-conjugated ECI2 antibody is a rabbit-derived polyclonal IgG antibody that binds specifically to the recombinant human ECI2 protein (amino acids 119–219) . FITC (Fluorescein Isothiocyanate), a green-emitting fluorophore, is covalently attached to lysine residues on the antibody, enabling fluorescent detection.
The ECI2 Antibody, FITC conjugated, has been pivotal in studies linking ECI2 to disease mechanisms, particularly in cancer.
ECI2 exhibits tumor-suppressive properties in CRC by inhibiting:
IL-8 Expression: Reduces interleukin-8 (IL-8) production, limiting neutrophil recruitment .
Neutrophil Extracellular Traps (NETosis): Suppresses NET formation, a pro-tumorigenic process .
Ether Lipid Synthesis: Inhibits alkylglycerone phosphate synthase (AGPS), reducing ether lipid intermediates .
Immunofluorescence: Detects ECI2 in CRC cells and metastatic tissues, correlating with reduced neutrophil infiltration .
Prognostic Value: Low ECI2 expression in CRC patients correlates with poor prognosis .
ECI2 regulates lipid metabolism by isomerizing 3-cis and 3-trans enoyl-CoA to 2-trans enoyl-CoA, a step critical for β-oxidation and ether lipid synthesis . Its inhibition of AGPS activity reduces ether lipids, which are precursors for pro-inflammatory cytokines like IL-8 .